IP Library Assignment 047288/0321
Patent Assignment
Reel/Frame 047288/0321

Security Interest

Recorded: 2018-08-06 Pages: 64
Assignor
NALPROPION PHARMACEUTICALS, INC.
Executed: 2018-07-27
Assignee
WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
500 DELAWARE AVENUE, WILMINGTON, DELAWARE, 19801
Covered Properties (28)
Compositions for Affecting Weight Loss
Patent: 7,375,111 →
Application: 10/828,795 →
Publication: US 2004/0254208
Compositions for Affecting Weight Loss
Patent: 7,462,626 →
Application: 11/356,839 →
Publication: US 2006/0142290
Compositions and methods for increasing insulin sensitivity
Patent: 8,815,889 →
Application: 11/602,571 →
Publication: US 2007/0128298
Sustained Release Formulation of Naltrexone
Patent: 8,916,195 →
Application: 11/757,773 →
Publication: US 2007/0281021
Layered Pharmaceutical Formulations
Patent: 8,088,786 →
Application: 11/937,421 →
Publication: US 2008/0113026
Methods for Administering Weight Loss Medications
Patent: 8,722,085 →
Application: 12/838,364 →
Publication: US 2011/0059170
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Patent: 9,248,123 →
Application: 12/987,909 →
Publication: US 2011/0172260
Layered Pharmaceutical Formulations
Patent: 8,318,788 →
Application: 13/330,395 →
Publication: US 2012/0093889
Increasing Drug Bioavailability in Naltrexone Therapy
Application: 13/991,137 →
Publication: US 2013/0245056
Methods for Reducing Binge or Compulsive Eating
Application: 13/991,372 →
Publication: US 2013/0252995
Methods for Administering Weight Loss Medications
Patent: 9,125,868 →
Application: 14/220,349 →
Publication: US 2014/0322318
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 8,969,371 →
Application: 14/322,810 →
Compositions and Methods for Increasing Insulin Sensitivity
Patent: 9,457,005 →
Application: 14/326,075 →
Publication: US 2014/0323399
Methods of Treating Overweight and Obesity
Patent: 9,633,575 →
Application: 14/405,775 →
Publication: US 2015/0154883
Sustained Release Formulation of Naltrexone
Patent: 9,107,837 →
Application: 14/555,475 →
Publication: US 2015/0080424
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,119,850 →
Application: 14/635,518 →
Publication: US 2015/0182524
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent: 9,801,875 →
Application: 14/839,792 →
Publication: US 2015/0366860
Methods for Administering Weight Loss Medications
Application: 14/844,476 →
Publication: US 2016/0193152
Layered Pharmaceutical Formulations
Application: 14/988,556 →
Publication: US 2016/0338965
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Application: 15/011,120 →
Publication: US 2016/0143903
Compositions and Methods for Reducing Major Adverse Cardiovascular Events
Application: 15/101,878 →
Publication: US 2016/0310485
Compositions for Affecting Weight Loss
Application: 15/276,600 →
Publication: US 2017/0007598
Sustained Release Formulation of Naltrexone
Application: 15/279,297 →
Publication: US 2017/0014404
Compositions and Methods for Increasing Insulin Sensitivity
Application: 15/284,357 →
Publication: US 2017/0020990
Compositions and Methods for Reducing Food Cravings
Application: 15/411,585 →
Publication: US 2017/0312269
Methods for Treating Visceral Fat Conditions
Application: 15/446,933 →
Publication: US 2017/0172999
Methods of Treating Overweight and Obesity
Application: 15/491,870 →
Publication: US 2017/0221380
Compositions and Methods for Weight Loss in at Risk Patient Populations
Application: 15/725,830 →
Publication: US 2018/0243288
Related Assignments (23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 9, 2012
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 029121/0736 →
Assignment of Assignor's Interest Jun 25, 2013
From: DUNAYEVICH, EDUARDO; MCELROY, SUSAN; LANDBLOOM, RON
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 030710/0299 →
Assignment of Assignor's Interest Mar 18, 2014
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 032463/0479 →
Assignment of Assignor's Interest Jul 15, 2014
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 033312/0523 →
Assignment of Assignor's Interest Oct 15, 2014
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 033953/0347 →
Assignment of Assignor's Interest Dec 18, 2015
From: DUNAYEVICH, EDUARDO; DEWITT (LEGAL REPRESENTATIVE OF GARY TOLLEFSON (DECEASED)), DAVID
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 037334/0490 →
Security Agreement Mar 21, 2016
From: OREXIGEN THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 038180/0021 →
Assignment of Assignor's Interest Mar 20, 2017
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041648/0257 →
Assignment of Assignor's Interest Mar 20, 2017
From: FLANAGAN, SHAWN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041646/0415 →
Assignment of Assignor's Interest Mar 20, 2017
From: DUNAYEVICH, EDUARDO
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041648/0415 →
Assignment of Assignor's Interest Mar 22, 2017
From: WEBER, ECKARD; COWLEY, MICHAEL ALEXANDER
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0847 →
Assignment of Assignor's Interest Mar 22, 2017
From: COWLEY, MICHAEL A; MCKINNEY, ANTHONY A.; TOLLEFSON, GARY
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0886 →
Assignment of Assignor's Interest Mar 22, 2017
From: MCKINNEY, ANTHONY A.; TOLLEFSON, GARY D.; SOLTERO, RICHARD; DUNZO, THEA ELISE
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0895 →
Assignment of Assignor's Interest Mar 22, 2017
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0934 →
Assignment of Assignor's Interest Mar 24, 2017
From: MCKINNEY, ANTHONY A.; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041734/0834 →
Assignment of Assignor's Interest Aug 2, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 046688/0661 →
Assignment of Assignor's Interest Sep 20, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047115/0102 →
Assignment of Assignor's Interest Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 048102/0478 →
Assignment of Assignor's Interest Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047960/0001 →
Assignment of Assignor's Interest Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047301/0786 →
Release of Security Interest Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050574/0106 →
Change of Name Oct 17, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: NALPROPION PHARMACEUTICALS LLC
Reel/Frame 050750/0497 →
Security Interest Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →